OBJECTIVE: This study assessed the relative value of using laboratory, claims, or integrated laboratory-claims data to identify prevalence rates and costs of metabolic syndrome among Chevron Texaco Corporation, San Ramon, California, employees. METHODS: This study identified five metabolic syndrome risk factors by using three identification methods: (1) health-screening data, applying the National Cholesterol Education Program Adult Treatment Panel III and World Health Organization definitions; (2) employer-based claims data applying proxy International Classification of Diseases, 9th Revision definitions; and (3) integrated laboratory-claims data. Prevalence rates and costs of metabolic syndrome and associated risk factors were estimated. RESULTS: Laboratory-defined and claims-defined approaches underestimated metabolic syndrome prevalence rates compared with the integrated approach by 22.9% and 87.5%, respectively. Employees with metabolic syndrome had double the costs of those without any risk factors ($4603 vs $1859; P = 0.0384). CONCLUSIONS: Results suggest that integrating laboratory and claims data is a more balanced approach than either approach alone for identifying metabolic syndrome among Chevron employees.
OBJECTIVE: This study assessed the relative value of using laboratory, claims, or integrated laboratory-claims data to identify prevalence rates and costs of metabolic syndrome among Chevron Texaco Corporation, San Ramon, California, employees. METHODS: This study identified five metabolic syndrome risk factors by using three identification methods: (1) health-screening data, applying the National Cholesterol Education Program Adult Treatment Panel III and World Health Organization definitions; (2) employer-based claims data applying proxy International Classification of Diseases, 9th Revision definitions; and (3) integrated laboratory-claims data. Prevalence rates and costs of metabolic syndrome and associated risk factors were estimated. RESULTS: Laboratory-defined and claims-defined approaches underestimated metabolic syndrome prevalence rates compared with the integrated approach by 22.9% and 87.5%, respectively. Employees with metabolic syndrome had double the costs of those without any risk factors ($4603 vs $1859; P = 0.0384). CONCLUSIONS: Results suggest that integrating laboratory and claims data is a more balanced approach than either approach alone for identifying metabolic syndrome among Chevron employees.
Authors: Sharon P Fowler; Sobha Puppala; Rector Arya; Geetha Chittoor; Vidya S Farook; Jennifer Schneider; Roy G Resendez; Ram Prasad Upadhayay; Jane Vandeberg; Kelly J Hunt; Benjamin Bradshaw; Eugenio Cersosimo; John L Vandeberg; Laura Almasy; Joanne E Curran; Anthony G Comuzzie; Donna M Lehman; Christopher P Jenkinson; Jane L Lynch; Ralph A Defronzo; John Blangero; Daniel E Hale; Ravindranath Duggirala Journal: Hum Genet Date: 2013-06-05 Impact factor: 4.132
Authors: Gerd Bobe; Tora J Cobb; Scott W Leonard; Savinda Aponso; Christopher B Bahro; Dipankar Koley; Eunice Mah; Richard S Bruno; Maret G Traber Journal: Redox Biol Date: 2017-02-14 Impact factor: 11.799
Authors: Marisol Perez; Laura K Winstone; Juan C Hernández; Sarah G Curci; Daniel McNeish; Linda J Luecken Journal: Pediatr Res Date: 2022-08-18 Impact factor: 3.953